Announcement • Mar 13
Hyundai Bioscience Co., Ltd., Annual General Meeting, Mar 26, 2026 Hyundai Bioscience Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 106, apo gongdan-gil, gyeongsangbuk-do, gimcheon South Korea New Risk • Jan 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (₩2.0b revenue, or US$1.4m). Announcement • Jan 15
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus Hyundai Bioscience announced a roadmap to combat global viral epidemics, officially declaring its entry into Phase 2 clinical trials in the United States. Presenting at the Biotech Showcase 2026, the company unveiled its pre-emptive therapeutic strategy using Xafty™?, a broad-spectrum antiviral drug. The presentation highlighted a bold transition: "Preparation in Vietnam is complete. Now, it is America". The core of the announcement centered on the clinical strategy designed in collaboration with Dr. Davey Smith, Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD). Dr. Smith, a world-renowned expert who previously led the U.S. government's ACTIV-2 COVID-19 trials, diagnosed the current U.S. healthcare crisis as a "tripledemic" of Influenza, RSV, and COVID-19 variants, for which there is no unified countermeasure. Hyundai Bioscience presented its unique "One Drug, Two Tracks" global strategy. The company is using the same drug (Xafty) to target: Dengue Fever in Vietnam (Track 1); Upper-Respiratory Infection Viruses in the US (Track 2). This approach validates the drug's breadth and potency, demonstrating its potential to treat both mosquito-borne and respiratory viral infections. This mechanism is analogous to modern antibiotics that can treat multiple bacterial types with a single drug. 